课题基金 / 基金详情

Developing a novel vaccine against COVID-19

Developing a novel vaccine against COVID-19
开发针对 COVID-19 的新型疫苗
批准号：
442945
负责人：
Divangahi Maziar
金额：
$41.52万
依托单位：
Research Institute of the McGill University Health Centre
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-11-01 至 2023-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=442945&lang=en
关键词：
Immune Response Respiratory Infection

项目摘要

项目成果

Divangahi Maziar的其他基金

相似基金

相关文献

中文摘要
翻译
危及生命的人类呼吸道病毒病原体，如SARS-Cov、MERS和目前的SARS-Cov-2的出现，对没有可用治疗干预措施的临床医生和必须迅速发展的科学家提出了严峻的挑战
英文摘要
The emergence of life-threatening human respiratory viral pathogens such as SARS-Cov, MERS, and current SARS-Cov-2 present an intense challenge to clinicians who are left with no available therapeutic interventions and scientists who must rapidly develop
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the eicosanoid/macrophage axis to enhance host defense against influenza virus infection
Reprogramming HSCs to generate protective trained immunity against TB
Monocyte/Macrophage Biology Symposium: Cracking the Macrophage Code in Host Defense and Tolerance
Regulation of Anti-Microbial Macrophage Response to Pulmonary Infections
海外基金